NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript | RLFTF Message Board Posts


Relief Therapeutics Holding AG

  RLFTF website

RLFTF   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  176 of 187  at  8/18/2021 11:20:32 AM  by

G3


 In response to msg 175 by  dkitt
view thread
Buy

Re: NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript

 We've applied for emergency use authorization for ZYESAMI in United states, and we hope for an FDA decision in turn within coming weeks. We've signed a logistics partnership with Cardinal Health in order that ZYESAMI, if it is approved for emergency use, can reach any patients in the U.S. within 24-hours. Our interpretation of our clinical trial results is that time is of the essence, when treating COVID.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...